Molecular Templates Inc. (MTEM) Financial Statements (2025 and earlier)

Company Profile

Business Address 9301 AMBERGLEN BLVD
AUSTIN, TX 78729
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:11,52361,000143,04493,885125,08497,955
Cash and cash equivalents11,52332,19024,98325,21885,45187,721
Short-term investments  57,718118,06168,66739,63310,234
Other undisclosed cash, cash equivalents, and short-term investments  (28,908)    
Receivables250  2347,508240
Prepaid expense2,1953,4593,9176,0802,3182,244
Other current assets2,8043,7901,2541,1254894,424
Other undisclosed current assets  49  4,500 
Total current assets:16,77268,298148,215101,324139,899104,863
Noncurrent Assets
Operating lease, right-of-use asset9,16111,1328,60811,1049,959
Property, plant and equipment7,39314,63219,30922,25418,1586,851
Long-term investments and receivables   8,986 1,510 
Long-term investments   8,986 1,510 
Restricted cash and investments      
Other noncurrent assets2,0573,4867,2445,1954,6761,821
Other undisclosed noncurrent assets     26,623
Total noncurrent assets:18,61129,25044,14738,55334,30335,295
TOTAL ASSETS:35,38397,548192,362139,877174,202140,158
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,8029,32711,12714,92516,0096,137
Accounts payable1,5235041,6122,3501,465780
Accrued liabilities4,2798,8239,51512,57514,5445,357
Deferred revenue 9,03145,57332,93714,01417,291
Debt      33
Other liabilities2,4882,1822,6062,2112,501141
Other undisclosed current liabilities    6,403 26,198
Total current liabilities:17,32157,08246,67037,55335,80132,509
Noncurrent Liabilities
Long-term debt and lease obligation  36,16845,05527,13914,6223,271
Long-term debt, excluding current maturities  36,16835,49114,9262,9403,254
Capital lease obligations17
Liabilities, other than long-term debt11,14819,43034,9756,02820,751819
Deferred revenue  5,90433,3504,53819,385
Other liabilities1,4061,2951,6251,4901,366816
Operating lease, liability9,74212,2319,56412,21311,682
Derivative instruments and hedges, liabilities      3
Other undisclosed noncurrent liabilities2,702  9,817 2,653
Total noncurrent liabilities:13,85055,59880,03042,98435,3736,743
Total liabilities:31,171112,680126,70080,53771,17439,252
Equity
Equity, attributable to parent4,212(15,132)65,66259,340103,028100,906
Common stock55656504637
Additional paid in capital457,099429,646417,704328,314267,089195,573
Accumulated other comprehensive income (loss)  (66)(48)1718 
Accumulated deficit(452,892)(444,768)(352,050)(269,041)(164,125)(94,704)
Total equity:4,212(15,132)65,66259,340103,028100,906
TOTAL LIABILITIES AND EQUITY:35,38397,548192,362139,877174,202140,158

Income Statement (P&L) ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues     22,27013,285
Gross profit:     22,27013,285
Operating expenses(67,772)(108,625)(118,771)(119,687)(92,719)(44,284)
Other undisclosed operating income57,30619,75438,69718,845  
Operating loss:(10,466)(88,871)(80,074)(100,842)(70,449)(30,999)
Nonoperating income
(Investment Income, Nonoperating)
     3 
Interest and debt expense 1,795(121)(146)(1,237)(2)(115)
Loss from continuing operations before equity method investments, income taxes:(8,671)(88,992)(80,220)(102,079)(70,448)(31,114)
Other undisclosed income (loss) from continuing operations before income taxes536(3,673)(2,789)(2,832)  
Loss from continuing operations before income taxes:(8,135)(92,665)(83,009)(104,911)(70,448)(31,114)
Income tax expense (benefit) 11(53) (5)  
Other undisclosed income from continuing operations      
Loss from continuing operations:(8,124)(92,718)(83,009)(104,916)(70,448)(31,114)
Loss before gain (loss) on sale of properties:(83,009)(104,916)(70,448)(31,114)
Other undisclosed net income      
Net loss:(8,124)(92,718)(83,009)(104,916)(70,448)(31,114)
Other undisclosed net income attributable to parent     1,027827
Net loss available to common stockholders, diluted:(8,124)(92,718)(83,009)(104,916)(69,421)(30,287)

Comprehensive Income ($ in thousands)

6/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(8,124)(92,718)(83,009)(104,916)(70,448)(31,114)
Other comprehensive income (loss) 66(18)(65)(1)18 
Other undisclosed comprehensive income      
Comprehensive loss:(8,058)(92,736)(83,074)(104,917)(70,430)(31,114)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    1,027827
Comprehensive loss, net of tax, attributable to parent:(8,058)(92,736)(83,074)(104,917)(69,403)(30,287)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: